
Roche
RHHVF | OTC
$483.84
-$3.66 (-0.75%)
At close: Nov 16, 2026, 3:37 PM ET
$489.00
+$5.16 (+1.07%)
Pre-market:
Nov 16, 2026, 9:35 AM ET
Roche Company Profile
Company profile explainedCompany Profile
Roche Holding AG operates as a global healthcare leader, specializing in both pharmaceuticals and diagnostics. The company's reach extends across key markets like Switzerland, Germany, and the United States, in addition to its broader international footprint. Its extensive pharmaceutical division develops and offers treatments for a diverse range of conditions. These therapeutic areas encompass critical fields such as oncology (cancer), neuroscience, infectious diseases, immunology, hemophilia, ophthalmology (eye care), dermatology (skin conditions), respiratory illnesses, anemia, inflammatory and autoimmune disorders, and transplantation. Beyond medicinal products, Roche is also a prominent supplier of in vitro diagnostic tests. These tests are vital for identifying numerous diseases, including various cancers, cardiovascular conditions, diabetes, COVID-19, hepatitis, and human papillomavirus (HPV). Complementing its testing services, the company provides the essential diagnostic instruments and chemical reagents necessary for these procedures. Demonstrating its commitment to innovation, Roche has established a research partnership with Synlogic, Inc. This collaboration aims to discover a novel synthetic biotic designed specifically for the treatment of inflammatory bowel disease (IBD). Tracing its origins back to its founding in 1896, Roche Holding AG is headquartered in Basel, Switzerland.
Key Executives
| Name | Position |
|---|---|
| Thomas Schinecker | Group Chief Executive Officer |
| Alan Hippe | Chief Financial Officer |
| Maria Cristina A. Wilbur | Chief People Officer |
| Boris L. Zaitra | Head of Corporate Business Development |
| Bruno Eschli | Head of Investor Relations |
| Claudia Bockstiegel | General Counsel |
| Nicolas Dunant | Head of Group Media Relations |
| Nina Schwab-Hautzinger | Head of Group Communications |
| Severin Schwan | Executive Chairman |
| Wafaa Mamilli | Chief Digital & Technology Officer |
Roche

| Country | Switzerland |
| IPO Date | Feb 13, 2009 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 103,249 |
| CEO | Thomas Schinecker |
Stock Details
| Ticker Symbol | RHHVF |
| Exchange | OTC |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | CH1499059983 |
| SIC Code | n/a |
Recent News
- 6 days ago / businesswire.comPerficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory Systems
- 15 days ago / prnewswire.comRoche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs
- 19 days ago / seekingalpha.comRoche: Valuation Leaves Limited Upside
- 20 days ago / seekingalpha.comBrown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors
- 22 days ago / wsj.comRoche Targets Emerging Oncology Market With New Lung-Cancer Drug
- 22 days ago / reuters.comRoche says divarasib cut risk of death 44% in lung cancer trial
- 23 days ago / globenewswire.comRoche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
- 23 days ago / businesswire.comGenentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
- 25 days ago / businesswire.comGenentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)
- 25 days ago / globenewswire.comRoche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Add to Watchlist
Select watchlists to add or remove RHHVF